A clinical study to evaluate the effect of Amritadhya Tailapana and Ashwagandha Ghritapana in patients with Hypothyroidism.

A Comparative Evaluation of the efficacy of Amritadhya tailapana and Ashwagandha Ghritapana in the management of Hypothyroidism(Galaganda). - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101814

Enrollment

Registered

2026-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E02- Subclinical iodine-deficiency hypothyroidism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient willing to participate in the study with written and informed consent. 2. 3. Patients with 6-10 IU TSH when peripheral thyroid hormone levels are within normal reference laboratory range. Patients having clinical features of Hypothyroidism. 4. Diagnosed as per ICD-11 code 5A40.0 with Hypothyroidism who are on regular Thyroxine (up to 25 Mcg). 5. 6. Patients between the ages of 20 to 50yrs. DAS SCALE-21 SCALE values mild to moderate

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1. Pregnant or lactating women. 2. Secondary Hypothyroidism. 3. Patient having any other major complicated disease like Diabetes mellitus, Cardiac disease, Tuberculosis, AIDS, etc. 4. Patients contraindicated for Snehapana. 5. Patients with TSH more than 10 IU. 6. DAS Scale -21 values severe to extremely severe.

Design outcomes

Primary

Measure	Time frame
Change in serum Thyroid Stimulating Hormone (TSH) levels from baseline to Day 60.Timepoint: Baseline and at the end of follow up on day 60	—

Secondary

Measure	Time frame
Change in serum T3 levels from baseline to Day 60. Change in serum T4 levels from baseline to Day 60. Improvement in clinical signs & symptoms of hypothyroidism (puffiness, edema, dry skin, constipation, lethargy, hair fall, menstrual irregularities) from baseline to Day 60. Change in DAS-21 score from baseline to Day 60. Assessment of safety & tolerability of the study drugs during the treatment period.Timepoint: Baseline (Day 0), end of treatment (Day 30), & end of follow-up (Day 60).	—

Measure

Time frame

Change in serum T3 levels from baseline to Day 60. Change in serum T4 levels from baseline to Day 60. Improvement in clinical signs & symptoms of hypothyroidism (puffiness, edema, dry skin, constipation, lethargy, hair fall, menstrual irregularities) from baseline to Day 60. Change in DAS-21 score from baseline to Day 60. Assessment of safety & tolerability of the study drugs during the treatment period.Timepoint: Baseline (Day 0), end of treatment (Day 30), & end of follow-up (Day 60).

—

Countries

India

Contacts

Public ContactDR ARUN GUPTA

Chaudhary Brahm Prakash Ayurved Charak Sansthan ,Khera Dabar

arun24@hotmail.com9999155377

Outcome results